Fundraising Fox

X-Vax Technology

New York, US · Founded 2015 · Delaware corporation · 5 known investors

Biotech

Founders & leadership

Board

IB
Isaac BlechVice Chairman
WA
William A. HaseltineBoard director
RP
Roger PomerantzBoard director
RR
Robert RuffoloBoard director

Investors · 5

Adjuvant CapitalreportedNew York · $10M – $25M
AlexandriareportedPasadena
Founders FundreportedSan Francisco · $500K – $5M
JJDCreportedNew Brunswick · $500K – $5M
Johnson & Johnson Innovation – JJDCreportedNew Brunswick

Reported raises · per SEC filings

Form D private placements

$56.6M disclosed across 2 rounds · 2016–2018

▶$56.5MraisedJul 2019 · 306 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ulf WiinbergExecutive Officer
  • Andreas EggertExecutive Officer
  • Jacob UittenbogaardExecutive Officer
  • Clare KahnExecutive Officer
  • Richard KenneyExecutive Officer
  • Ian T. ClarkDirector
  • Matthew StoberDirector
  • Brian D. FinnDirector
  • William A. HaseltineDirector
  • Roger JeffsDirector
  • Roger J. PomerantzDirector
  • Robert R. RuffoloDirector
  • Isaac BlechDirector
Offering amount
$58M
Amount sold
$56.5M
Minimum investment
$20K
Sales commissions
$5.6M
Placement agents
Maxim Group LLC
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedSep 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William A. HaseltineDirector
  • Isaac BlechExecutive Officer, Director
  • Roger PomerantzDirector
  • Robert RuffoloDirector
Offering amount
$1M
Amount sold
$100K
Minimum investment
$25K
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

X-Vax packs $56m into series A round -globalventuring.com · Jul 2019BioCentury - July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and morebiocentury.com · Jul 2019“Beating Herpes”: Adjuvant’s First Investment Targets a Daunting Viral Infection | by Adjuvant Capital | Mediummedium.com · Jul 2019X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program - BioSpacebiospace.com · Jul 2019X-Vax Technology Secures $56M in Series A Financing - FinSMEsfinsmes.com · Jul 2019X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Programprnewswire.com · Jul 2019

Frequently asked questions

Who are X-Vax Technology's investors?
X-Vax Technology's investors include Adjuvant Capital, Alexandria, Founders Fund, JJDC, Johnson & Johnson Innovation – JJDC.
How much funding has X-Vax Technology raised?
X-Vax Technology has disclosed $56.6M raised across 2 rounds.
Where is X-Vax Technology headquartered?
X-Vax Technology is headquartered in New York, US.